Skip to main content

Table 1 Statistical power based on average number of febrile attacks

From: Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial

   TCZ groupa
1 1.5 2
Placebo groupa 5.5 91.5 80 65.8
6 94.5 86.1 73.3
6.5 96.2 90 79.8
  1. TCZ Tocilizumab
  2. aThe average number of febrile attacks during 24 weeks in each group is shown